Loss-of-function (LOF) mutations affecting CREBBP are also recurrent second-hit mutations across multiple genetic subtypes of B-ALL and are associated with adverse features, including high-risk genetic subtypes and persistent measurable residual disease (MRD)4–7. This evidence concerns the gene CREBBP and acute lymphoblastic leukemia.